Received Jul 2, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | — | — |
Inappropriate schedule of vaccine (1 month apart); This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too short in the unspecified the number of patients who received Men B NVS (Bexsero) for prophylaxis. Concomitant products included Meningococcal vaccine B rfHbp/NadA/NHBA OMV (Bexsero). On an unknown date, the patients received the 2nd dose of Bexsero. On an unknown date, an unknown time after receiving Bexsero, the patient experienced drug dose administration interval too short (Verbatim: Inappropriate schedule of vaccine (1 month apart)). The outcome of the drug dose administration interval too short was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 17-JUN-2025 General Response Center (did not raise an adverse event report) transferred a Nurse Manager that asked that they were following the previous Prescribing Information administering doses one month apart to some of the patients, which led to drug dose administration interval too short. They want to know if the patients have to receive a third dose, a booster, or what should they do? No vaccination date, no vaccine detail and no patient demographics were obtained in this call. No further information was obtained in this call.
Bexsero